Stacie S. Aarestad

Representative Experience

• Good Start Genetics in a merger with genetic information company Invitae Corporation (NYSE: NVTA)
• Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) in its initial public offering of common stock
• Zosano Pharma Corporation (NASDAQ:  ZSAN) $29.3 million underwritten public offering of common stock
• Zosano Pharma $7.5 million PIPE of units (common stock and warrants) with warrants exercisable for an additional $14.4 million
• Dyax Corp. (NASDAQ: DYAX) in its sale to Shire plc.
• Dyax Corp. in public securities offerings including:
  • $230,000,000 underwritten public offering of common stock
  • $80,000,000 underwritten public offering of common stock
  • $65,000,000 underwritten public offering of common stock
  • $30,000,000 registered direct offering of common stock
  • $63,537,500 underwritten public offering of common stock
  • $21,000,000 underwritten public offering of common stock
  • $17,250,000 underwritten public offering of common stock
  • $50,000,000 Committed Equity Financing Facility with Azimuth Opportunity Ltd.
  • $44,300,000 underwritten public offering of common stock
• Dyax Corp. in connection with secured loans including:
  • $65,000,000 loan agreement with Cowen Healthcare Royalty Partners, L.P., consisting of a $50,000,000 Tranche A loan and a $15,000,000 Tranche B loan, secured by Dyax’s phage display Licensing and Funded Research Program
  • $30,000,000 royalty interest assignment agreement with Paul Capital Partners
• Bolt Technology Corporation (NASDAQ: BOLT) in its sale to Teledyne Technologies Incorporated (NYSE: TDY)
• NewStar Financial, Inc. (NASDAQ: NEWS) in securities offerings:
  • $300,000,000 144A offering of 7.25% Senior Notes due 2020
  • $125,000,000 PIPE with institutional investors including, Corsair Capital, Union Square Partners and Och-Ziff Capital Management, Swiss Re and SAB Capital
• Lamar Advertising Company (NASDAQ: LAMR) in its REIT conversion
• Lamar Advertising Company and its wholly owned subsidiary Lamar Media Corp. in high yield and convertible debt offerings and tender offers including:
  • $400,000,000 144A offering of 5 3/4% Senior Notes due 2026
  • $510,000,000 144A offering of 5 ⅜% Senior Notes due 2024 with follow-on exchange offer
  • $535,000,000 144A offering of 5% Senior Subordinated Notes due 2023 with follow-on exchange offer
  • $500,000,000 144A offering of 5 ⅞% Senior Subordinated Notes due 2022 with follow-on exchange offer
  • $400,000,000 144A offering of 7 ⅞% Senior Subordinated Notes due 2018 with follow-on exchange offer
  • Cash Tender Offer and Consent Solicitation for all of Lamar’s then outstanding 7 ¼% Senior Subordinated Notes due 2013
  • Tender Offer to eligible employees and directors to exchange certain outstanding options to purchase the Company's Class A common stock for a lesser number of new options
  • Cash Tender Offers for all of Lamar’s then outstanding 2 ⅞% Convertible Notes due 2010—Series B
  • $350,000,000 144A offering of 9 ¾% Senior Notes due 2014 with follow-on exchange offer
  • $275,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015—Series C with follow-on exchange offer
  • Exchange Offer of a new series of 2 ⅞% Convertible Notes due 2010—Series B for all outstanding 2 ⅞% Convertible Notes due 2010
  • $216,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015—Series B with follow-on exchange offer
  • $400,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015 with follow-on exchange offer